News
-
-
-
-
PRESS RELEASE
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
Menarini Group presents data from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at EHA 2026 Congress, showing significant spleen volume reduction and potential overall survival benefit -
-
-
-
-
-
PRESS RELEASE
EQS-Adhoc: AT&S Austria Technologie & Systemtechnik AG: AT&S expands AI substrate capacity in Kulim and increases outlook for 2026/27
AT&S Austria Technologie & Systemtechnik AG expands AI substrate capacity in Kulim, Malaysia, increasing outlook for 2026/27 with significant revenue growth and EBITDA margin expansion